HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Bungo Shirasawa Kimikazu Hamano Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, T.-S. Articles by Hamano, K. Search for Related Content PubMed Articles by Li, T.-S. Articles by Hamano, K. Related Collections Transplantation - heart

J Thorac Cardiovasc Surg 2007;134:1347-1349
© 2007 The American Association for Thoracic Surgery

Brief Communication

Long-term efficacy and safety of the intramyocardial implantation of autologous bone marrow cells for the treatment of ischemic heart disease

Department of Surgery and Clinical Science, Division of Cardiovascular Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.

Received for publication May 28, 2007; revisions received June 19, 2007; accepted for publication July 12, 2007.

^_* Address for reprints: Kimikazu Hamano, MD, PhD, Department of Surgery and Clinical Science, Division of Cardiovascular Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, Japan 755-8505. (Email: litaoshe@yamaguchi-u.ac.jp).

The first 20% of the full text of this article appears below.

The delivery of autologous bone marrow–derived cells has developed as a revolutionary concept for repairing the injured heart,¹ and many clinical trials have been conducted all over the world. Although there are conflicting reports about the beneficial effects of bone marrow cells for myocardial repair,² early- and middle-phase clinical trials have not found any severe side effects of cell-based therapy. However, its long-term safety and feasibility have not yet been established. We report the results of more than 5 years’ follow-up of patients treated with the intramyocardial injection of autologous bone marrow mononuclear cells (BM-MNCs) after coronary artery bypass grafting (CABG).

Clinical Summary

Between November 1999 and March 2002, 8 selected patients undergoing standard CABG were given an intramyocardial injection of BM-MNCs into the ungrafted ischemic area (Table 1). The collection and separation of BM-MNCs was detailed previously.¹ After the completion of CABG, 322 x 10⁸ BM-MNCs were injected directly, with 622 injections, into the targeted area, where there was no indication for CABG or intervention therapy (Figure 1). To determine the safety and feasibility of this therapy, we monitored the . . . [Full Text of this Article]

This article has been cited by other articles:

				T.-S. Li, M. Kubo, K. Ueda, M. Murakami, A. Mikamo, and K. Hamano Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure J. Thorac. Cardiovasc. Surg., February 1, 2010; 139(2): 459 - 465. [Abstract] [Full Text] [PDF]

				T.-S. Li, M. Kubo, K. Ueda, M. Murakami, M. Ohshima, T. Kobayashi, T. Tanaka, B. Shirasawa, A. Mikamo, and K. Hamano Identification of Risk Factors Related to Poor Angiogenic Potency of Bone Marrow Cells From Different Patients Circulation, September 15, 2009; 120(11_suppl_1): S255 - S261. [Abstract] [Full Text] [PDF]